Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

A 5-year-old boy died in an explosion at a medical facility in Troy, Mich., on Friday, Jan. 31, according to the Troy Fire Department. The young child, whose identity has not been revealed, was in a ...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

The Food and Drug Administration (FDA) has approved Omvoh ® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults. Mirikizumab is a humanized immunoglobulin G4 ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

You'd think blowing your nose when you've got a cold is pretty self explanatory, but apparently most of us have been doing it wrong our whole lives. Insoo Hyun, a Bioethicist and the Director of the ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Wearable devices can identify ...

The senior vice president at Lilly Immunology Development discusses recent developments with Omvoh. The European Medicines Agency’s Committee for Medicinal Products for Human Use recently issued a ...

The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug Administration ...

The recent approval of Omvoh for Crohn's disease, following its success in ulcerative colitis, demonstrates Eli Lilly's commitment to broadening its therapeutic reach. One of the key challenges ...